2 Information about enzalutamide

2 Information about enzalutamide

Marketing authorisation indication

Enzalutamide (Xtandi, Astellas) has a marketing authorisation 'for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer'.

Dosage in the marketing authorisation

Enzalutamide is administered orally at a dose of 160 mg (4×40 mg soft capsules) daily.


£2,734.67 per 112 capsules (excluding VAT; British national formulary online, accessed December 2018) The daily dose comprises 4 capsules and costs £97.67.

The company has a commercial arrangement which would apply if the technology had been recommended.

  • National Institute for Health and Care Excellence (NICE)